Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions.
Publication/Presentation Date
4-1-2017
Abstract
PURPOSE OF REVIEW: Major strides have been made in the treatment of kidney cancer in the last several years with checkpoint immunotherapies and novel targeted agents. This manuscript will review current treatment strategies for metastatic renal cell carcinoma and will discuss future directions.
RECENT FINDINGS: Most recently, several new drugs including nivolumab, cabozantinib, and a combination of lenvatinib and everolimus have demonstrated acceptable toxicity and significantly improved overall survival, but evidence-based guidelines for sequencing of the approved treatment options and treatment selection based on biomarkers are still missing. Despite the significant progress, many questions still remain unanswered. Several ongoing clinical trials are evaluating sequencing, timing of cytoreductive nephrectomy, combinations of immunotherapies and targeted therapies as well as selection of the best systemic treatment. Personalized treatment based on tumor profiling is one of the brightest spots on the horizon.
Volume
19
Issue
4
First Page
27
Last Page
27
ISSN
1534-6269
Published In/Presented At
Merza, H., & Bilusic, M. (2017). Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Current oncology reports, 19(4), 27. https://doi.org/10.1007/s11912-017-0583-8
Disciplines
Medicine and Health Sciences
PubMedID
28303494
Department(s)
Department of Medicine
Document Type
Article